UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 25.

Achhra, A C; Mocroft, A; Reiss, P; Sabin, C; Ryom, L; de Wit, S; Smith, C J; d'Arminio Monforte, A; Phillips, A; Weber, R; Lundgren, J; Law, M G (2016). Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. HIV Medicine, 17(4):255-268.

Mocroft, A; Furrer, H J; Miro, J M; Reiss, P; Mussini, C; Kirk, O; Abgrall, S; Ayayi, S; Bartmeyer, B; Braun, D; Castagna, A; d'Arminio Monforte, A; Gazzard, B; Gutierrez, F; Hurtado, I; Jansen, K; Meyer, L; Muñoz, P; Obel, N; Soler-Palacin, P; Papadopoulos, A; Raffi, F; Ramos, J T; Rockstroh, J K; Salmon, D; Torti, C; Warszawski, J; de Wit, S; Zangerle, R; Fabre-Colin, C; Kjaer, J; Chene, G; Grarup, J; Lundgren, J D (2013). The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clinical Infectious Diseases, 57(7):1038-1047.

Worm, S W; Kamara, D A; Reiss, P; Fontas, E; De Wit, S; El-Sadr, W; D'Arminio Monforte, A; Law, M; Phillips, A; Ryom, L; Dabis, F; Weber, R; Sabin, C; Lundgren, J D (2012). Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke. Journal of Infectious Diseases, 205(4):535-539.

Kowalska, J D; Reekie, J; Mocroft, A; Reiss, P; Ledergerber, B; Gatell, J; D'Arminio Monforte, A; Phillips, A; Lundgren, J D; Kirk, O (2012). Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS, 26(3):315-323.

Vrouenraets, S M E; Wit, F W N M; Garcia, E Fernandez; Huber, M; Brinkman, K; Moyle, G; Domingo, P; Tarr, P E; Podzamczer, D; Ristola, M; Gatell, J M; Livrozet, J M; Furrer, H; Reiss, P (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clinical Trials, 13(2):103-110.

Murray, M; Hogg, R S; Lima, V D; May, M T; Moore, D M; Abgrall, S; Bruyand, M; D'Arminio Monforte, A; Tural, C; Gill, M J; Harris, R J; Reiss, P; Justice, A; Kirk, O; Saag, M; Smith, C J; Weber, R; Rockstroh, J; Khaykin, P; Sterne, J A C (2012). The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis. HIV Medicine, 13(2):89-97.

Reekie, J; Reiss, P; Ledergerber, B; Sedlacek, D; Parczewski, M; Gatell, J; Katlama, C; Fätkenheuer, G; Lundgren, J D; Mocroft, A (2011). A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. HIV Medicine, 12(5):259-268.

Petoumenos, K; Worm, S; Reiss, P; de Wit, S; D'Arminio Monforte, A; Sabin, C; Friis-Møller, N; Weber, R; Mercie, P; Pradier, C; El-Sadr, W; Kirk, O; Lundgren, J; Law, M (2011). Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study. HIV Medicine, 12(7):412-421.

Arenas-Pinto, A; Grant, A; Bhaskaran, K; Copas, A; Carr, A; Worm, S W; Martinez, E; Reiss, P; Dunn, D; Weber, R; Hoy, J; Weller, I (2011). Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. Antiviral Therapy, 16(2):219-226.

Thompson, M A; Aberg, J A; Cahn, P; Montaner, J S G; Rizzardini, G; Telenti, A; Gatell, J M; Günthard, H F; Hammer, S M; Hirsch, M S; Jacobsen, D M; Reiss, P; Richman, D D; Volberding, P A; Yeni, P; Schooley, R T (2010). Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA: The Journal of the American Medical Association, 304(3):321-333.

Mocroft, A; Phillips, A N; Ledergerber, B; Smith, C; Bogner, J R; Lacombe, K; Wiercinska-Drapalo, A; Reiss, P; Kirk, O; Lundgren, J D (2010). Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Antiviral Therapy, 15(4):563-570.

Mocroft, A; Kirk, O; Reiss, P; De Wit, S; Sedlacek, D; Beniowski, M; Gatell, J; Phillips, A N; Ledergerber, B; Lundgren, J D (2010). Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 24(11):1667-1678.

Smith, C J; Sabin, C A; Lundgren, J D; Thiebaut, R; Weber, R; Law, M; D'Arminio Monforte, A; Kirk, O; Friis-Moller, N; Phillips, A; Reiss, P; El Sadr, W; Pradier, C; Worm, S W (2010). Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. AIDS, 24(10):1537-1548.

Weber, R; Sabin, C; Reiss, P; De Wit, S; Worm, S W; Law, M; Dabis, F; D'Arminio Monforte, A; Fontas, E; El-Sadr, W; Kirk, O; Rickenbach, M; Phillips, A; Ledergerber, B; Lundgren, J (2010). HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D cohort study. Antiviral Therapy, 15(8):1077-1086.

Friis-Møller, N; Thiebaut, R; Reiss, P; Weber, R; Monforte, A D; De Wit, S; El-Sadr, W; Fontas, E; Worm, S W; Kirk, O; Phillips, A; Sabin, C A; Lundgren, J D; Law, M G (2010). Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. European Journal of Cardiovascular Prevention and Rehabilitation, 17(5):491-501.

Worm, S W; Sabin, C; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Fontas, E; Weller, I; Phillips, A; Lundgren, J (2010). Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. Journal of Infectious Diseases, 201(3):318-330.

Mocroft, A; Reiss, P; Gasiorowski, J; Ledergerber, B; Kowalska, J; Chiesi, A; Gatell, J; Rakhmanova, A; Johnson, M; Kirk, O; Lundgren, J (2010). Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. Journal of Acquired Immune Deficiency Syndrome, 55(2):262-270.

Lodwick, R; Costagliola, D; Reiss, P; Torti, C; Teira, R; Dorrucci, M; Ledergerber, B; Mocroft, A; Podzamczer, D; Cozzi-Lepri, A; Obel, N; Masquelier, B; Staszewski, S; García, F; De Wit, S; Castagna, A; Antinori, A; Judd, A; Ghosn, J; Touloumi, G; Mussini, C; Duval, X; Ramos, J; Meyer, L; Warsawski, J; Thorne, C; Masip, J; Pérez-Hoyos, S; Pillay, D; van Sighem, A; Lo Caputo, S; Günthard, H; Paredes, R; De Luca, A; Paraskevis, D; Fabre-Colin, C; Kjaer, J; Chêne, G; Lundgren, J D; Phillips, A N (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Archives of Internal Medicine, 170(5):410-419.

Worm, S W; De Wit, S; Weber, R; Sabin, C A; Reiss, P; El-Sadr, W; Monforte, A D; Kirk, O; Fontas, E; Dabis, F; Law, M G; Lundgren, J D; Friis-Møller, N (2009). Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation, 119(6):805-811.

Peters, L; Mocroft, A; Soriano, V; Rockstroh, J K; Losso, M; Valerio, L; Aldins, P; Reiss, P; Ledergerber, B; Lundgren, J D (2009). Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(5):457-463.

D'Arminio Monforte, A; Abramson, D; Pradier, C; Weber, R; Reiss, P; Bonnet, F; Kirk, O; Law, M; De Wit, S; Friis-Møller, N; Phillips, A N; Sabin, C A; Lundgren, J D (2008). HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS, 22(16):2143-2153.

Sabin, C A; d'Arminio Monforte, A; Friis-Moller, N; Weber, R; El-Sadr, W M; Reiss, P; Kirk, O; Mercie, P; Law, M G; De Wit, S; Pradier, C; Phillips, A N; Lundgren, J D (2008). Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clinical Infectious Diseases, 46(7):1101-1110.

Podlekareva, D; Mocroft, A; Kirk, O; Reiss, P; Aldins, P; Katlama, C; Kovari, H; Stellbrink, H J; D'Arminio Monforte, A; Lundgren, J D (2008). Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scandinavian Journal of Infectious Diseases, 40(11):908-913.

De Wit, S; Sabin, C A; Weber, R; Worm, S W; Reiss, P; Cazanave, C; El-Sadr, W; D'Arminio Monforte, A; Fontas, E; Law, M G; Friis-Møller, N; Phillips, A (2008). Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care, 31(6):1224-1229.

Sabin, C A; Worm, S W; Weber, R; Reiss, P; El-Sadr, W; Dabis, F; De Wit, S; Law, M; D'Arminio Monforte, A; Friis-Møller, N; Kirk, O; Pradier, C; Weller, I; Phillips, A N; Lundgren, J D; D:A:D Study Group (2008). Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 371(9622):1417-1426.

This list was generated on Wed Jul 26 17:06:24 2017 CEST.